

# Menicon Co., Ltd. Medium-Term Management Plan

Securities Code: 7780

Menicon Co., Ltd. May 14, 2024

Partially revised and added on November 13, 2024.

[Revisions and additions] p.18, p.36, p.37, p.38

Please refer to [Appendix] on the last page for the revised and added parts.



- 1 Menicon's Goals
- 2 Contact Lens Market Environment
- 3 Milestone 2025 Progress Assessment
- 4 Set Milestone 2027
- 5 Growth Strategies (1DAY-lens Growth Strategy and Orthokeratology-Related Growth Strategy)
- 6 Capital Allocation, Shareholder Return Policy
- 7 Management with cost of capital and stock price in mind



- 1 Menicon's Goals
- 2 Contact Lens Market Environment
- 3 Milestone 2025 Progress Assessment
- 4 Set Milestone 2027
- 5 Growth Strategies (1DAY-lens Growth Strategy and Orthokeratology-Related Growth Strategy)
- 6 Capital Allocation, Shareholder Return Policy
- 7 Management with cost of capital and stock price in mind

### Menicon's Goals



### **Sustainability Policy**

<Our Goal> To achieve a healthy and spiritually rich society

#### Vision2030

New Vision of 'Miru' for the World

Top Global Player of 1DAY-lens Business **Leading Company of Orthokeratology-related Business** 

Mid-term Management

#### **Expansion of 1DAY-lens Business**

**Build Foundation of Myopia Control Related Business** 

**Provide New** Value through the five senses

Plan

#### **Domestic**

Strengthen Foundation of MELS Plan

Balanced Growth in Europe, North America and Asia

**Overseas** 

Contributing to a happy

Materiarity

Providing a lifestyle that stimulates the five senses

Building a corporate infrastructure that will last 100 years

Reducing impact on the global environment

society

**Increase in Myopic Population** 

Climate Change

Respect for **Human Rights** 























































# Menicon's Goal -Growth Strategy Policy



#### **Ideal State of Menicon**

#### **Corporate Slogan**

Contributing to society by providing superior visual correction

#### Vision2030

New Vision of 'Miru' for the World



#### Social Issue

Increase in Global Myopia Population

Lower Age of Myopia and Increase in High Myopia

#### **Company that Solves Social Issues**

# Menicon's Goal (Growth Strategy Policy) 1DAY-lens Strategic Policy Aim to be Aim to be Top Global Player of 1DAY-lens Business with original products and services Orthokeratology-related (Myopia Control-related) Strategic Policy Aim to be Leading Company of Orthokeratology-related (Myopia Control-related) Business by creating new value related to myopia control



- 1 Menicon's Goals
- **2** Contact Lens Market Environment
- 3 Milestone 2025 Progress Assessment
- 4 Set Milestone 2027
- 5 Growth Strategies (1DAY-lens Growth Strategy and Orthokeratology-Related Growth Strategy)
- 6 Capital Allocation, Shareholder Return Policy
- 7 Management with cost of capital and stock price in mind

# Increase in Myopia Population



### Myopia population continues to grow.




Exhibit: World Health Organization, "THE IMPACT OF MYOPIA AND HIGH MYOPIA"




# Widespread use of contact lenses



# Expected to increase global contact lens penetration by increasing number of ECP (Eye Care Practitioners)

### Number of ECP per million population




Source: Euromonitor International. Eyewear (2023) / Countries covered: China, Hong Kong, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, Australia, Poland, Romania, Russia, Ukraine, Argentina, Brazil, Mexico, South Africa, United Arab Emirates, Canada, USA, France, Germany, Italy, Netherlands, Spain, Sweden, Switzerland, Turkey, United Kingdom

ECP...Ophthalmologists, optometrists, etc. who prescribe contact lenses and eyeglasses. The number of ECP is used as an indicator of contact lens penetration.

### Growth potential of the global contact lens market (1DAY-lens)




### Growth mainly in 1DAY-lens due to convenience 1DAY-lens accounting for 60% of the market



# Growth potential of global 1DAY-lens market (Silicone material)



### Silicone material 1DAY-lens drives growth in 1DAY-lens





# Lower Age of Myopia and Increase in High Myopia



Due to the spread of digital devices etc, the global myopia population is becoming younger and the number of high myopia people is increasing.

There are high expectations for efforts to myopia control because of concern about increasing risk of future eye diseases.






THE IMPACT OF MYOPIA AND HIGH MYOPIA

### Growth Potential of Global Orthokeratology Lens Market



### **Expect to grow steadily**





- 1 Menicon's Goals
- 2 Contact Lens Market Environment
- **3 Milestone 2025 Progress Assessment**
- 4 Set Milestone 2027
- 5 Growth Strategies (1DAY-lens Growth Strategy and Orthokeratology-Related Growth Strategy)
- 6 Capital Allocation, Shareholder Return Policy
- 7 Management with cost of capital and stock price in mind

# Milestone 2025 Progress Assessment



# Changes in the external environment affected the progress of Milestone 2025 (Quantitative Target FY2025)

	Target (FY2025)	Track Record (FY2023)	Evaluation (Change in business environment)		Future Initiatives
	Net Sales JPY 140.0 bn	Net Sales JPY 116.1 bn	Covid-19		
Quantitative Target			Careful decision of 1DAY-lens investment due to temporary stagnation in the contact	$\triangle$	<ul><li>1DAY-lens Supply System</li><li>Strengthen of supply chain</li></ul>
	OP margin 12 %	OP margin	Pop margin 8 %  ROE due to supply chain disruptions  Rising procurement costs and pressure on earnings due to accelerating inflation  AY-lens Ratio  AY-lens Ratio		<ul> <li>Strengthen of profitability</li> <li>Appropriate price revision</li> <li>Reduce manufacturing costs by the effect of mass production</li> </ul>
	ROE	^			
	10 %	6 %			Balanced growth in priority regions
Strategic Target	33%  MELS Members MELS	1DAY-lens Ratio 27% MELS Members			<ul> <li>Strengthen1DAY-lens sales</li> </ul>
			Growth of OEM supply of 1DAY-lens in Europe/USA	0	Japan: Increase in 1DAY-lens ratio of MELS  Europe/North America: Expand OEM  • Strengthen Orthokeratology-related sale
		1.34M	Ortho-K growth acceleration of China (~2023/9)	0	
	Overseas Ratio 35 %	Overseas Ratio 32 %	Ortho-K growth stabilization of China (2023/10~)	rowth stabilization of China China: Stab	




- 1 Menicon's Goals
- 2 Contact Lens Market Environment
- 3 Milestone 2025 Progress Assessment
- 4 Set Milestone 2027
- 5 Growth Strategies (1DAY-lens Growth Strategy and Orthokeratology-Related Growth Strategy)
- 6 Capital Allocation, Shareholder Return Policy
- 7 Management with cost of capital and stock price in mind

# Menicon Growth History



### Sales growth of 1DAY-lens and Orthokeratology-related business through MELS Plan and M&A



### Set Milestone 2027



### Set Milestone 2027 (new quantitative target: FY2027) based on changes in the environment.


	Stable Growth phase	Investment phase		Investment Return phase
	FY2019	FY2023		FY2027 Quantitative Targets
Net sales	JPY 84.5 bn	JPY 116.1 bn	1DAY-lens Strategy	Over JPY <b>140.0</b> bn
Operating profit ratio	8 %	8 %	Orthokeratology- related strategy	12%.
ROE	9 %	6 %	Transform Profit Structure by executing Strategy	12%.

#### Set ROIC as an internal target

- Promote management that is focused on return on capital
- Aim to shift the profit structure from "investment phase" to "Investment Return phase"

### Set Milestone 2027






### Set Milestone 2027



### Aim to improve profitability through 1DAY-lens mass production effect of Malaysian plant





- 1 Menicon's Goals
- 2 Contact Lens Market Environment
- 3 Milestone 2025 Progress Assessment
- 4 Set Milestone 2027
- 5 Growth Strategies (1DAY-lens Growth Strategy and Orthokeratology-Related Growth Strategy)
- 6 Capital Allocation, Shareholder Return Policy
- 7 Management with cost of capital and stock price in mind

# Growth Strategy Targets & 1DAY-lens Regional Targets



### **Expect to achieve goals by implementing growth strategies**






- 1 Menicon's Goals
- 2 Contact Lens Market Environment
- 3 Milestone 2025 Progress Assessment
- 4 Set Milestone 2027
- 5 Growth Strategies (1DAY-lens Growth Strategy and Orthokeratology-Related Growth Strategy)
- 6 Capital Allocation, Shareholder Return Policy
- 7 Management with cost of capital and stock price in mind

# 1DAY-lens Production Capacity



### Increase in 1DAY-lens sales due to strengthen production capacity


#### 1DAY-lens Production Capacity and 1DAY-lens Sales\* Transition





# 1DAY-lens Capital Investment and Sales

### **Expand 1DAY-lens sales through capital investment in Malaysia plant**



# Strengths of Menicon




### Expand sales through unique SMART TOUCH package and region-specific sales strategies

#### **Unique products**

### **SMART TOUCH package**

No need to change the handle, no touching the inner surface.







#### **Menicon's Core Values**

- Over 70 years in business
- Trust in Japanese Quality
- Commitment to Innovation
- Environmentally friendly product design

#### **Sales Strategy by Region**

Japan

- MELS Plan in approx. 1,600 stores
- Utilization of approx. 170 group stores

Europe & North America

• Expand sales to major volume retail chains

Asia

• Expand sales by group companies

\*Including the development of new sales channels through M&A

Number of countries where products are exhibited:

approx. 60



# Malaysia Plant Overview

As for Phase1, Production is scheduled to start in 2025. Malaysia plant can be expanded up to 4 times the scale depending on demand.

Phase1 (on going)

Phase2~4 (Undecided: expanded based on demand)

Specifications that allow installation of multiple types of manufacturing equipment to meet demand



Office building and logistics/packaging building can accommodate the expansion of production capacity in the Phase2

Malaysia plant overview

	manayora prant o tortron						
	[Phase1]						
Product Capacity	Up to 500 million pieces/year						
Total amount of investment	<ul> <li>Approx. JPY 50.0 bn</li> <li>(Buildings: production, office, logistics and packaging)</li> <li>Already carried out: Approx. JPY 21.0 bn</li> <li>FY2024 - FY2027: approx. JPY 29.0 bn (tentative)</li> </ul>						
Schedule	Production is scheduled to start in 2025						



	[Phase2]	[Phase3~4]	
Additional production capacity	Up to 500 million lenses/year (tentative)	Up to 1.0 billion lenses/year (tentative)	
Additional investment	Approx. JPY 27.0 bn (tentative) (Buildings :only production)	undecided	
Schedule	undecided	undecided	

### 1DAY-lens market and Menicon's share



### Establish a global sales base by developing sales and supply chain

⇒Expand market share by increasing supply of the product

#### **Establish a foundation in Japan**

**Expand 1DAY-lens market share mainly in** 

Japan: 1DAY-lens market and Menicon's share

#### **Product**


Launch of Magic

#### **Poduction enhancement**

Singapore Plant

#### Strengthen domestic sales

 Expand directly managed stores



#### **Product**


Launch of 1DAY PremiO Series

#### **Production enhancement**

- Singapore Plant
- Kakamigahara Plant

#### Strengthen domestic sales

· Acquire Retail Chain



\*OEM-supplied products are not included in our sales figures (Internal survey data ).

#### **Establish a global infrastructure**

**Expanding 1DAY-lens market shar** Global


Global: 1DAY-lens Market and Menicon's share


#### **Production enhancement**

- Singapore Plant
- Kakamigahara Plant

#### Strengthen global sales

Alliance with a major mass





#### **Production enhancement** Malaysia Plant

- Singapore Plant
- Kakamigahara Plant

#### Strengthen global sales

 Started operation of logistics subsidiary



2027 (Forecast)

14.6 bn

Lenses

1DAY-lens Market CAGR

+4%

Menicon CAGR

+10%

\*OEM-supplied products are not included in our sales figures (Internal survey data ).

26




















































































































- 1 Menicon's Goals
- 2 Contact Lens Market Environment
- 3 Milestone 2025 Progress Assessment
- 4 Set Milestone 2027
- 5 Growth Strategies (1DAY-lens Growth Strategy and Orthokeratology-Related Growth Strategy)
- 6 Capital Allocation, Shareholder Return Policy
- 7 Management with cost of capital and stock price in mind

# Orthokeratology-Related Sales



### Expect stable growth based on demand to myopia control



### **Orthokeratology-Related Strategy Measures**

Orthokeratology Lenses: Expand global sales with multiple product features

Lens Care Products: Expand sales by diversifying sales channels



# Orthokeratology-Related Sales Strategy

Orthokeratology Lenses (Global): Sales through "Multiple products" and "Expansion to other countries" Lens Care Products (Asia): Sales through multiple channels (medical/EC)

#### **Orthokeratology Lenses (Global)**

#### α Ortho-K

- · Product features: Highly customized
- Sales area: Japan / China / Asia

#### **Menicon Z Night**

- Product features: High oxygen permeability
   Software to support prescription
- Sales area: Europe / China / Asia

#### **Menicon Bloom Night**

- Product features: Myopia control management approval
- Sales area: Europe / Asia

Number of countries where products are exhibited: about  $\bf 35$ 

#### **Lens Care Products (Asia)**

#### MeniCare Plus

 Product features: Cleaning, disinfection and preservation solution
 High cleaning and disinfection effectiveness

#### **Progent**


Product features: Protein remover
 High cleaning effectiveness

Expand sales through medical/EC channels



# Orthokeratology Lens Market and Menicon Share






# Growth by Executing Growth Strategies



Aim to achieve targets by executing two growth strategies (1DAY-lens & Orthokeratology-related)






- 1 Menicon's Goals
- 2 Contact Lens Market Environment
- 3 Milestone 2025 Progress Assessment
- 4 Set Milestone 2027
- 5 Growth Strategies (1DAY-lens Growth Strategy and Orthokeratology-Related Growth Strategy)
- 6 Capital Allocation, Shareholder Return Policy
- 7 Management with cost of capital and stock price in mind

# Capital Allocation, Shareholder Return Policy




#### Four-year cumulative total (FY2024 – FY2027)



# Shareholder Return Policy



### Stable Dividend with a payout ratio approx. 30%






- 1 Menicon's Goals
- 2 Contact Lens Market Environment
- 3 Milestone 2025 Progress Assessment
- 4 Set Milestone 2027
- 5 Growth Strategies (1DAY-lens Growth Strategy and Orthokeratology-Related Growth Strategy)
- 6 Capital Allocation, Shareholder Return Policy
- 7 Management with cost of capital and stock price in mind

### Return on Capital and Market Valuation Trends



- PBR increased due to higher ROE from profit growth and higher PER from growth expectations for **Vision Care business, in the past**
- FY2023, PBR declined to around 1.3x due to a temporary slowdown in profit growth caused by accelerated growth investment and changes in growth expectations



ROE **Profit Growth** 

#### FY2015 ~ FY2022 (Increase) 1 2



- Increase in 1DAY-lens sales ratio
- · Growth of orthokeratology-related business in China

#### FY2023 (Temporary decrease) 3



- Temporary decrease in profitability due to 1DAY-lens growth investments
- Slowdown in growth of orthokeratology-related business due to economic stagnation in China

#### **PER Growth Expectations**

#### FY2015 ~ FY2020 (Increase) 1



- Increase in number of MELS Plan members
- Growth of orthokeratology-related business in China

#### FY2021 ~ FY2023 (Decrease) 2 3




- Change in expectations due to 1DAY-lens supply restrictions
- · Change in expectations due to stabilization of Orthokeratologyrelated market growth in China

## Actions to Improve PBR




Profit growth through execution of 1DAY-lens/Orthokeratology-related strategies (ROE improvement) and creating growth expectations (PER improvement) by achieving mid-term management plan milestones





### Promote sustainability management and improve ESG ratings

Review policies and initiatives in line with materiality, and promote initiatives for items that have not yet been addressed.



# Disclaimer on Forward-Looking Statements



#### **Disclaimer**

- This document was created by Menicon Co., Ltd. (hereinafter referred to as the "Company") for the purpose of understanding the current situation of the Company in order to serve as a reference for investors.
- The contents of this document have been prepared based on the generally recognized economic and social conditions as of May 14, 2024 and certain assumptions that the Company deems reasonable. The contents are subject to change without notice due to changes in the business environment
- When making an investment, please be sure to make your own judgment.

#### Notes on forward-looking statements

- The document and information provided in this presentation include so-called "forward-looking statements". These are based on current expectations, forecasts and risks assumptions and contain uncertainties that could lead to results that are substantially different from these statements.
- These risks and uncertainties include general industry and market conditions, general domestic and international economic conditions such as interest rates and currency exchange fluctuations.
- Even if there is new information or future events, we are not obligated to update or revise the "outlook information" included in this announcement.

#### **Contact information**

Menicon Co., Ltd.

Finance & Investor Relations Team, Corporate Planning & Controlling Dept.

E-mail: menicon-ir@menicon.co.jp www.menicon.co.jp/company

# [Appendix]



### On November 13, 2024, the following part of the "Medium-Term Management Plan" was revised.

p.18

- Ratio of COGS (FY2024 (Forecast)): 47.1% (Before revision 46.9%)
- · Ratio of SG&A (FY2024 (Forecast)): 44.7% (Before revision 45.0%)

#### Set Milestone 2027







# [Appendix]



### On November 13, 2024, the following slides of the "Medium-Term Management Plan" were added.

Copyright: Menicon Co., Ltd. All rights reserved


p.36, p.37

· Slides addition

#### Return on Capital and Market Valuation Trends



- PBR increased due to higher ROE from profit growth and higher PER from growth expectations for Vision Care business, in the past
- FY2023, PBR declined to around 1.3x due to a temporary slowdown in profit growth caused by accelerated growth investment and changes in growth expectations



#### Actions to Improve PBR



Profit growth through execution of 1DAY-lens/Orthokeratology-related strategies (ROE improvement) and creating growth expectations (PER improvement) by achieving mid-term management plan milestones



# [Appendix]



### On November 13, 2024, the following slides of the "Medium-Term Management Plan" was added.

Copyright: Menicon Co., Ltd. All rights reserved.

p.38

· Slides addition

#### Promote sustainability management and improve ESG ratings



Review policies and initiatives in line with <u>materiality</u>, <u>and</u> promote initiatives for items that have not yet been addressed.

